Literature DB >> 23411563

Synthesis and structure-activity relationship studies of novel tubulysin U analogues--effect on cytotoxicity of structural variations in the tubuvaline fragment.

Sreejith P Shankar1, Monika Jagodzinska, Luciana Malpezzi, Paolo Lazzari, Ilaria Manca, Iain R Greig, Monica Sani, Matteo Zanda.   

Abstract

Tubulysins are cytotoxic natural products with promising anti-cancer properties, originally isolated from myxobacterial cultures. Structurally, tubulysins are tetrapeptides, incorporating three unusual (Mep, Tuv and Tup) and one proteinogenic amino acid (Ile). Here we describe the synthesis and structure-activity relationship studies of novel tubulysin U and V analogues, with variations in the central Tuv fragment, which is known to be of paramount importance for tubulysins' potency and hence cytotoxicity, but has seldom been modified in previous studies. Specifically, we replaced the natural iso-propyl and acetoxy functionalities with other structurally related groups. In general, the new analogues showed much lower potency relative to native tubulysin U. However, one of the synthetic analogues (1f) having a MOM function replacing the acetyl group exhibited a 22 nM IC50 on the HT-29 cell line which is comparable to the IC(50) displayed by tubulysin U (3.8 nM). Furthermore, the synthetic methodology reported herein was found to be flexible enough to deliver different core-modified tubulysin analogues and hence may be regarded as a scalable and convenient strategy for the chemical generation of novel tubulysin analogues.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23411563     DOI: 10.1039/c3ob27111k

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  7 in total

1.  Structural convergence for tubulin binding of CPAP and vinca domain microtubule inhibitors.

Authors:  Valérie Campanacci; Agathe Urvoas; Liza Ammar Khodja; Magali Aumont-Nicaise; Magali Noiray; Sylvie Lachkar; Patrick A Curmi; Philippe Minard; Benoît Gigant
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-04       Impact factor: 12.779

2.  Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.

Authors:  Michal Stark; Yehuda G Assaraf
Journal:  Oncotarget       Date:  2017-07-25

3.  Diastereocontrol in Radical Addition to β-Benzyloxy Hydrazones: Revised Approach to Tubuvaline and Synthesis of O-Benzyltubulysin V Benzyl Ester.

Authors:  Manshu Li; Koushik Banerjee; Gregory K Friestad
Journal:  J Org Chem       Date:  2021-10-12       Impact factor: 4.354

4.  Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.

Authors:  Joseph A Reddy; Ryan Dorton; Alicia Bloomfield; Melissa Nelson; Christina Dircksen; Marilynn Vetzel; Paul Kleindl; Hari Santhapuram; Iontcho R Vlahov; Christopher P Leamon
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

Review 5.  Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.

Authors:  Hao Chen; Zongtao Lin; Kinsie E Arnst; Duane D Miller; Wei Li
Journal:  Molecules       Date:  2017-08-01       Impact factor: 4.411

6.  Synthesis of Menthol Glycinates and Their Potential as Cooling Agents.

Authors:  Douglas A Klumpp; Robert M Sobel; Smaro G Kokkinidou; Brian Osei-Badu; Zachary Liveris; Rachel A Klumpp; Michael R Stentzel
Journal:  ACS Omega       Date:  2020-02-13

7.  Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific Conjugation.

Authors:  Joseph Z Hamilton; Thomas A Pires; Jamie A Mitchell; Julia H Cochran; Kim K Emmerton; Margo Zaval; Ivan J Stone; Martha E Anderson; Steven Jin; Andrew B Waight; Robert P Lyon; Peter D Senter; Scott C Jeffrey; Patrick J Burke
Journal:  ChemMedChem       Date:  2021-02-12       Impact factor: 3.540

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.